Zyprexa Zydis(Olanzapine)
LLY
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Eli Lilly and Company
$3.0M
Medicare cost, 2024
$3.0M
Medicare cost, 2024
Medicare drug plans spent $3.0 million on Zyprexa Zydis (olanzapine) in 2024, for 1,754 prescriptions and refills filled by 254 patients. California accounts for the most spending ($601,617, 20% of the total). It is made by Eli Lilly and Company (LLY).
Medicare cost, 2024
$3.0M
-13.0% from 2023
Prescriptions
1,754
$1,724.03 per claim
Patients
254
336 prescribers
Total spending, 2024
$3.0M
$11,877.08 per patient
Questions and answers
How much does Medicare spend on Zyprexa Zydis?
Medicare prescription drug plans paid $3.0M for Zyprexa Zydis in 2024, for 1,754 prescriptions and refills to 254 patients (down 13.0% from 2023). The average cost per claim was $1,724.03.
Which state spends the most on Zyprexa Zydis?
California had the highest Medicare cost for Zyprexa Zydis in 2024: $602K for 315 claims, followed by New York ($295K).
Who prescribes Zyprexa Zydis the most?
Stephen Grelecki, psychiatry in Elizabeth, NJ, had the highest Medicare cost for Zyprexa Zydis in 2024: 26 claims costing $83K.
Who makes Zyprexa Zydis?
Zyprexa Zydis is made by Eli Lilly and Company (LLY), listed in the Medicare spending data as Eli Lilly & Co..
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Zyprexa Zydis was $3.0M in 2024, after a high of $4.2M in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Zyprexa Zydis, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Stephen Grelecki Elizabeth, NJ | Psychiatry | 26 | Under 11 | $83K |
| Douglas Sears Encino, CA | Specialist | 13 | Under 11 | $59K |
| Jennifer L Stanley Lansing, MI | Psychiatry | 13 | Under 11 | $39K |
| Andrea D Morrow Clearwater, FL | Nurse Practitioner | 11 | Under 11 | $34K |
| Ronald J Wauters Searcy, AR | Psychiatry | 12 | Under 11 | $31K |
| Bradley Brooks Mobile, AL | Psychiatry | 11 | Under 11 | $31K |
| Maria C Abeleda Wytheville, VA | Psychiatry | 11 | Under 11 | $31K |
| Ricardo E Sanchez Arecibo, PR | Psychiatry & Neurology | 13 | Under 11 | $31K |
| Said Jacob Glendora, CA | Psychiatry | 26 | Under 11 | $28K |
| Jeffrey F Johns Berkeley, CA | Psychiatry & Neurology | 22 | Under 11 | $27K |
| Rebecca Parry Jacksonville, FL | Nurse Practitioner | 12 | Under 11 | $25K |
| Janice M Montgomery-Suber Honolulu, HI | Nurse Practitioner | 14 | Under 11 | $25K |
| Magdalena E Szklarska-Imiolek Rochester, NY | Psychiatry | 12 | Under 11 | $25K |
| Gerard Deeney Philadelphia, PA | Psychiatry | 26 | Under 11 | $24K |
| Navneet Bains Yuba City, CA | Psychiatry | 20 | Under 11 | $23K |
| David B Vanholla Norway, MI | Psychiatry & Neurology | 22 | Under 11 | $23K |
| Kara J Jeffas Bend, OR | Nurse Practitioner | 11 | Under 11 | $23K |
| Vanessa Baker Pearland, TX | Nurse Practitioner | 11 | Under 11 | $23K |
| Salome Tsurtsumia Farmington, CT | Nurse Practitioner | 11 | Under 11 | $22K |
| Bong Doan Westminster, CA | Psychiatry | 13 | Under 11 | $22K |
| Gianine Burgo Rochester, NY | Nurse Practitioner | 22 | Under 11 | $21K |
| Yvette A Elpidio Orange, CA | Certified Clinical Nurse Specialist | 14 | Under 11 | $20K |
| Jared M Nelson Rialto, CA | Psychiatry & Neurology | 13 | Under 11 | $20K |
| Berylla Sarfo San Antonio, TX | Nurse Practitioner | 13 | Under 11 | $20K |
| Angela J Soder Lima, OH | Psychiatry | 13 | Under 11 | $18K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 365 | 2,178 | 277 | $3.6M |
| 2023 | 371 | 2,117 | 259 | $3.5M |
| 2024 | 336 | 1,754 | 254 | $3.0M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Eli Lilly & Co. | 1,766 | $3.0M |
Codes
- National drug codes (packages)
- 4
- RxNorm concept IDs
- 153046, 153047, 153048, 200034, 212405
- Application numbers
- NDA021086
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through June 2026, 108,127 side-effect reports named olanzapine, the active ingredient of Zyprexa Zydis (reports from 2003 on). 92,336 of them (85.4%) were serious, 13,205 named a death and 47,221 named a hospital stay. The reactions named most often were drug ineffective, weight increased and off label use. 32,831 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
108,127
7,455 in 2025 (+1.9% from 2024)
Serious
85.4%
92,336 reports
Deaths named
13,205
12.2% of reports
Hospital stays
47,221
43.7% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Zyprexa Zydis?
108,127 reports from 2003 through June 2026 named olanzapine, the active ingredient of Zyprexa Zydis. 92,336 of them (85.4%) were serious, 13,205 named a death and 47,221 named a hospital stay.
What are the most reported side effects of Zyprexa Zydis?
7,418 reports named drug ineffective, the reaction named most often, followed by weight increased (6,902) and off label use (6,239). In the last 5 years the reaction named most often was drug ineffective (3,182 reports). A report can name several reactions.
How many side-effect reports named Zyprexa Zydis in 2025?
7,455 reports were received in 2025 (+1.9% from 2024). 2026 so far: 3,448 reports through June 2026, and more keep arriving late.
Do side-effect reports prove that Zyprexa Zydis caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Zyprexa Zydis caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with olanzapine: Olanzapine, Olanzapine Odt, Zyprexa, Olanzapine*, Zyprexa*
- Makers on the stock market:
LLY·LLY drug pipeline - Drug approvals (28 approvals on file for olanzapine) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (olanzapine) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.